Latest news
Please click on the headings below to be directed to the stories:
Myeloma UK teams up with prestigious European Nursing Groups
The pan-European nursing collaboration will support nurses across Europe to deliver the best treatment and care to myeloma patients.
Myeloma early diagnosis campaign smashes target 6 months early
During National Myeloma Week 2009 Myeloma UK kicked off a year-long campaign to help ensure fewer myeloma patients experience a delay in diagnosis.
Myeloma patients and family members make key recommendations to NICE
Following a successful discussion event with myeloma patients and family members, Myeloma UK has made recommendations to NICE on how it assesses new treatments.
Mozobil (plerixafor)® is approved for use in Scotland
The Scottish Medicines Consortium (SMC) announced today that myeloma patients in Scotland will have access to the ‘stem cell mobiliser’ drug Mozobil (plerixafor).
Myeloma UK welcome Lois Dawber to the team
We are delighted to welcome Lois Dawber to Myeloma UK. Lois joined Myeloma UK just before Christmas and takes up the reigns of our healthcare professional education and awareness programmes.
US study shows promising results for lenalidomide post transplant
Newly-published findings from a myeloma study show promising results for the use of lenalidomide following high-dose therapy and stem cell transplantation.
Eden Financial supports Myeloma UK at its annual charity trading day
Myeloma UK was delighted to receive an extremely generous donation of £50,000 from Eden Financial.
Biosimilar drug filgrastim (Ratiograstim™▼) is approved for use in Scotland
The biosimilar drug filgrastim (Ratiograstim™▼) has been approved for use on the NHS in Scotland.
Myeloma UK attended the 2009 Britain against Cancer conference
The 11th annual Britain against Cancer conference took place in London on 1 December 2009. Myeloma UK attended this year’s conference where the main theme was cancer inequalities.
Metage Capital Ltd Donates to Myeloma UK
Myeloma UK was delighted to receive an extremely generous donation of £10,000 recently from Metage Capital Ltd, an investment management firm based in London.
New Infoguide on the Myeloma X Relapse (Intensive) Study now available
Myeloma UK has produced a new Myeloma Infoguide about the UK-wide Myeloma X Relapse (Intensive) clinical study. The Infoguide is available to download here or you can contact us for a printed copy.
Myeloma UK responds to the Care and Support Consultation
Myeloma UK has responded to the Government consultation on its plans for the establishment of a new National Care Service in England.
Myeloma UK succeeds in joining leading medical research charities on the AMRC
Myeloma UK succeeds in joining the leading medical and health research charities in the UK with membership of the Association of Medical Research Charities (AMRC).
Velcade approved for use in Scotland
Myeloma UK welcomes the news that the Scottish Medicines Consortium (SMC) has today approved Velcade® (bortezomib) for relapsing myeloma patients in Scotland.
Myeloma UK launches the Myeloma Clinical Trial Network
Myeloma UK has today launched a first-of-its-kind national Clinical Trial Network designed to transform the way drugs for myeloma are tested and accessed in the UK.
European Commission grants orphan drug status for myeloma drug pomalidomide
The European Commission has granted ‘orphan drug’ status for the new myeloma drug pomalidomide.
Myeloma UK welcomes the 3rd International Workshop on Myeloma Pharmacogenomics
Myeloma UK welcomes the 3rd International Workshop on Myeloma Pharmacogenomics. The workshop will take place in Edinburgh on the 7 and 8 October and will investigate how genetic factors affect the way myeloma patients respond to certain drugs.
Myeloma UK wants to hear your experiences of the Care and Support system
The Government in England is consulting on a number of proposals to underpin a new National Care Service. Myeloma UK is keen to hear from you to help us respond to the consultation.
Data suggests genetic link between environmental toxins and myeloma bone disease
New data suggests a possible genetic link between environmental toxins and myeloma bone disease.
Mozobil ™ is granted licence in EU to aid stem cell collection in myeloma patients
The European Commission has granted a marketing licence for Mozobil™ for use by myeloma patients preparing for autologous stem cell transplantation.
New Myeloma Infosheets on Prescription Charges and Copayments now available
Myeloma UK has produced new Myeloma Infosheets on Prescription Charges and Copayments (top-ups). The Infosheets are available to download here or you can contact us for printed copies.
Velcade-Caelyx turned down by SMC for use in Scotland
The Scottish Medicines Consortium (SMC) has decided not to recommend Velcade in combination with Caelyx for myeloma patients in Scotland.